Wells Fargo & Company Hille Vax, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HLVX
# of Institutions
80Shares Held
36.8MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$19.4 Million1.01% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$9 Million0.74% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.83 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.58 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.45 Million0.06% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $61.2M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.